LogBB - Revision history

Kirilas: Fixed broken links

2022-10-14T12:01:55Z

Fixed broken links

← Older revision		Revision as of 12:01, 14 October 2022
Line 38:		Line 38:

	<div class="mw-collapsible-content">		<div class="mw-collapsible-content">
	Only a short summary of main technical aspects of BBB penetration predictors is given here. For a more detailed description of the modeling approach and underlying theory please refer to Lanevskij, K. et al. ''J Pharm Sci.'' '''2009''';98(1):122-34. [~~http~~://~~www3~~.~~interscience~~.~~wiley~~.~~com/journal/119140960~~/~~abstract~~]		Only a short summary of main technical aspects of BBB penetration predictors is given here. For a more detailed description of the modeling approach and underlying theory please refer to Lanevskij, K. et al. ''J Pharm Sci.'' '''2009''';98(1):122-34. [https://pubmed.ncbi.nlm.nih.gov/21271563]

	===Calculated quantitative parameters===		===Calculated quantitative parameters===
Line 80:		Line 80:
	===Prediction accuracy===		===Prediction accuracy===

	Prior to development of both log ''PS'' and log ''BB'' predictive models a part of each data set was reserved for validation purposes and not used in modeling (internal validation set). Additionally, two independent data sets representing another type of experimental data (directly measured ''f<sub>u, brain</sub>'' values) were extracted from recent publications (Kalvass J. C. et al. ''Drug Metab Dispos.'' '''2007''';35(4):660-6 [http://dmd.aspetjournals.org/cgi/content/full/35/4/660], and Summerfield S. G. et al. ''Xenobiotica.'' '''2008''';38(12):1518-35. [~~http~~://~~www~~.~~informaworld~~.~~com/smpp/content~db=all?content=10~~.~~1080~~/~~00498250802499459~~]) These were used as external validation sets to confirm intrinsic correctness of the obtained model.		Prior to development of both log ''PS'' and log ''BB'' predictive models a part of each data set was reserved for validation purposes and not used in modeling (internal validation set). Additionally, two independent data sets representing another type of experimental data (directly measured ''f<sub>u, brain</sub>'' values) were extracted from recent publications (Kalvass J. C. et al. ''Drug Metab Dispos.'' '''2007''';35(4):660-6 [http://dmd.aspetjournals.org/cgi/content/full/35/4/660], and Summerfield S. G. et al. ''Xenobiotica.'' '''2008''';38(12):1518-35. [https://pubmed.ncbi.nlm.nih.gov/18979396]) These were used as external validation sets to confirm intrinsic correctness of the obtained model.

	Performance of the models on various validation sets is presented in the table below:		Performance of the models on various validation sets is presented in the table below:

Kirilas at 09:58, 15 June 2017

2017-06-15T09:58:19Z

← Older revision		Revision as of 09:58, 15 June 2017
Line 32:		Line 32:


	<div class="mw-collapsible ~~mw-collapsed~~">		<div class="mw-collapsible">

	==Technical information==		==Technical information==

Kristina: /* Overview */

2012-05-29T13:13:28Z

Overview

← Older revision		Revision as of 13:13, 29 May 2012
Line 9:		Line 9:
	* Displays carrier-mediated transport alerts for compounds that undergo facilitated diffusion or active efflux across BBB		* Displays carrier-mediated transport alerts for compounds that undergo facilitated diffusion or active efflux across BBB
	* Displays experimental LogBB values for up to three most similar compounds from the model training set along with literature references		* Displays experimental LogBB values for up to three most similar compounds from the model training set along with literature references
			<br />

	== Interface ==		== Interface ==

Kristina at 13:12, 29 May 2012

2012-05-29T13:12:59Z

← Older revision		Revision as of 13:12, 29 May 2012
Line 13:		Line 13:
	<br />		<br />

	[[Image:~~bbb_logbb~~.png\|center]]		[[Image:Bbb_logbb.png\|center]]
	<br />		<br />

Line 24:		Line 24:

	</li>		</li>
	<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound<br>[[File:~~bbb_logbb_scale~~.png\|300px]]</li>		<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound<br>[[File:Bbb_logbb_scale.png\|300px]]</li>
	<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>		<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>
	<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>		<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>
Line 40:		Line 40:

	===Calculated quantitative parameters===		===Calculated quantitative parameters===
	BBB module in ~~[[Pharma_Algorithms_Product_Info#ADME_Boxes\|ADME Boxes]]~~ calculates the following quantitative characteristics of drug transport across blood-brain barrier:		BBB module in calculates the following quantitative characteristics of drug transport across blood-brain barrier:

	'''Main parameters:'''		'''Main parameters:'''
Line 64:		Line 64:
	intraperitoneal or oral) administration to rats and mice yielded a data set of log BB values for about		intraperitoneal or oral) administration to rats and mice yielded a data set of log BB values for about
	600 compounds. The collected data were thoroughly evaluated to ensure that they represent BBB transport by passive		600 compounds. The collected data were thoroughly evaluated to ensure that they represent BBB transport by passive
	diffusion ~~(see [[BBB#Transport_mechanisms\|Transport mechanisms]])~~. The resulting data sets after preliminary analysis contained almost 200 log ''PS'' constants and almost 500 log ''BB'' ratios.		diffusion. The resulting data sets after preliminary analysis contained almost 200 log ''PS'' constants and almost 500 log ''BB'' ratios.

	===Modeling method & used descriptors===		===Modeling method & used descriptors===

Kirilas: /* Features */

2012-05-24T14:39:43Z

Features

← Older revision		Revision as of 14:39, 24 May 2012
Line 5:		Line 5:

	===Features===		===Features===
	* ~~Provides a unified interface that summarizes all relevant information regarding BBB penetration potential of the compound of interest~~		* Calculates the extent of brain penetration (LogBB) and fraction unbound in brain tissue (f<sub>u,brain</sub>)
	* Classifies the compound as CNS permeable on non-permeable and displays the values of quantitative parameters supporting the ~~prediction:~~
	** Rate of brain penetration (~~LogPS~~)
	** Extent of brain ~~penetration~~ (~~LogBB)~~
	** Brain/plasma equilibration rate (Log (PS * ''f''<sub>u, brain</sub>))
	* Visualizes the predictions using the 'traffic lights' scheme showing which parameters preclude brain delivery of the analyzed compound
	* Allows altering the values of main physicochemical determinants to get an insight on structural changes needed to achieve desired permeation characteristics		* Allows altering the values of main physicochemical determinants to get an insight on structural changes needed to achieve desired permeation characteristics
	* Displays a scatter plot providing a possibility to compare relevant brain penetration characteristics of the analyzed compound to a set of well-known CNS and peripheral drugs.
	* Displays carrier-mediated transport alerts for compounds that undergo facilitated diffusion or active efflux across BBB		* Displays carrier-mediated transport alerts for compounds that undergo facilitated diffusion or active efflux across BBB
	~~<br />~~		* Displays experimental LogBB values for up to three most similar compounds from the model training set along with literature references

	== Interface ==		== Interface ==

Kristina: /* Interface */

2012-05-17T11:46:46Z

Interface

← Older revision		Revision as of 11:46, 17 May 2012
Line 30:		Line 30:

	</li>		</li>
	<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound<br>[[File:bbb_logbb_scale.png\|~~400px~~]]</li>		<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound<br>[[File:bbb_logbb_scale.png\|300px]]</li>
	<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>		<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>
	<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>		<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>

Kristina: /* Interface */

2012-05-17T11:45:23Z

Interface

← Older revision		Revision as of 11:45, 17 May 2012
Line 28:		Line 28:

	:b. Click to recalculate the unbound fraction in brain and LogBB using the currently specified parameter values		:b. Click to recalculate the unbound fraction in brain and LogBB using the currently specified parameter values

	~~:c. Switch between Pharma Algorithms and ACD/Labs algorithms for calculation of physicochemical properties~~

	</li>		</li>
	<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound</li>		<li> Calculated values of unbound fraction in brain (''f''<sub>u, brain</sub>) and LogBB of a compound<br>[[File:bbb_logbb_scale.png\|400px]]</li>
	<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>		<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>
	<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>		<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>

Kristina: Created page with "==Overview==
This module provides mechanistic predictions of blood brain distribution of drugs and drug-like compounds in rodents. The predictive model is based on a d..."

2012-05-17T11:30:50Z

Created page with "==Overview== This module provides mechanistic predictions of blood brain distribution of drugs and drug-like compounds in rodents. The predictive model is based on a d..."

New page

==Overview==
 

This module provides mechanistic predictions of blood brain distribution of drugs and drug-like compounds in rodents. The predictive model is based on a data-set containing >500 brain to plasma partitioning ratios (expressed as LogBB constants) measured in mice and rats. Under the assumption of passive transport across blood-brain barrier LogBB is viewed as a cumulative effect of drug binding to plasma and brain constituents. Calculations therefore use octanol/water logP (main determinant of brain tissue binding) and unbound fraction in plasma (''f''u, plasma) as input parameters. 

===Features===
* Provides a unified interface that summarizes all relevant information regarding BBB penetration potential of the compound of interest
* Classifies the compound as CNS permeable on non-permeable and displays the values of quantitative parameters supporting the prediction:
** Rate of brain penetration (LogPS)
** Extent of brain penetration (LogBB)
** Brain/plasma equilibration rate (Log (PS * ''f''u, brain))
* Visualizes the predictions using the 'traffic lights' scheme showing which parameters preclude brain delivery of the analyzed compound
* Allows altering the values of main physicochemical determinants to get an insight on structural changes needed to achieve desired permeation characteristics
* Displays a scatter plot providing a possibility to compare relevant brain penetration characteristics of the analyzed compound to a set of well-known CNS and peripheral drugs.
* Displays carrier-mediated transport alerts for compounds that undergo facilitated diffusion or active efflux across BBB
 

== Interface ==
 

[[Image:bbb_logbb.png|center]]
 

<ol>
<li> logP and fraction unbound in plasma (''f''u, plasma) are calculated automatically. Alter these values to simulate the limiting effect of the compound's lipophilicity and/or plasma protein binding on its brain disposition. [[Image:BBB_logbb_Simulation.png|right]]

:a. Click the "Undo" button to restore the automatically calculated property value (''f''u, plasma in the current example) for a compound and recalculate LogBB using default parameter values

:b. Click to recalculate the unbound fraction in brain and LogBB using the currently specified parameter values

:c. Switch between Pharma Algorithms and ACD/Labs algorithms for calculation of physicochemical properties

</li>
<li> Calculated values of unbound fraction in brain (''f''u, brain) and LogBB of a compound</li>
<li> Up to 3 most similar structures from the training set of the model with experimental values and references</li>
<li> An alert is shown if the compound is likely to exhibit other Blood-Brain Barrier transport mechanisms apart from passive diffusion: carrier-mediated influx or P-gp efflux</li>
</ol>
 

<div class="mw-collapsible mw-collapsed">

==Technical information==
 

<div class="mw-collapsible-content">
Only a short summary of main technical aspects of BBB penetration predictors is given here. For a more detailed description of the modeling approach and underlying theory please refer to Lanevskij, K. et al. ''J Pharm Sci.'' '''2009''';98(1):122-34. [http://www3.interscience.wiley.com/journal/119140960/abstract]

===Calculated quantitative parameters===
BBB module in [[Pharma_Algorithms_Product_Info#ADME_Boxes|ADME Boxes]] calculates the following quantitative characteristics of drug transport across blood-brain barrier:

'''Main parameters:'''
* Rate of brain penetration (Log ''PS''). PS stands for Permeability-Surface area product and is defined from the kinetic equation of capillary transport (''PS'' = -''F'' * (1 - e''-Kin/F'')). By Its physical meaning ''PS'' is equal to the influx rate constant ''Kin'' corrected for blood flow rate in cerebral microcapillaries denoted as ''F''.
* Extent of brain penetration (Log ''BB'') determined by ratio of total drug concentrations in tissue and plasma at steady-state conditions (log ''BB'' = log(''cbrainSS/cbloodSS).

'''Additional parameters:'''
* Fraction unbound in brain tissue (''fu, brain'')
* Brain/plasma equilibration rate given by log (''PS'' * ''fu, brain) - combination of permeation rate and fraction unbound in brain.

When only single parameter values are considered ''fu, brain'' provides a better insight on drug disposition in CNS than Log ''BB'' since the former provides a direct estimate of tissue binding affinity/free (pharmacologically active) drug levels in brain, while the latter represents a superposition of compounds' binding to brain lipids and plasma proteins. However, both equilibrium distribution ratio (Log ''BB'') and the rate of achieving this equilibrium (defined as log (''PS'' * ''fu, brain'') according to Liu X. et al. ''J Pharmacol Exp Ther.'' '''2005''';313(3):1254-62. [http://jpet.aspetjournals.org/cgi/content/full/313/3/1254]) must be evaluated to estimate whether enough compound permeates through BBB to reach pharmacologically active levels in brain.

===Experimental data===
The data sets used for modeling were compiled from
original literature publications of BBB permeation studies in rodents. Quantitative log ''PS'' data were collected for
more than 250 compounds. These were determined by one of the following experimental methods:

* Intravenous administration (IV)
* Brain uptake index (BUI)
* ''In situ'' brain perfusion.

Analysis of published brain/plasma distribution studies of drugs after intravenous (in some cases –
intraperitoneal or oral) administration to rats and mice yielded a data set of log BB values for about
600 compounds. The collected data were thoroughly evaluated to ensure that they represent BBB transport by passive
diffusion (see [[BBB#Transport_mechanisms|Transport mechanisms]]). The resulting data sets after preliminary analysis contained almost 200 log ''PS'' constants and almost 500 log ''BB'' ratios.

===Modeling method & used descriptors===
The predictive models of log ''PS'' and log ''BB'' constants were built using non-linear least squares regression. Non-linear fitting was necessary to account for the following aspects of the analyzed processes:

* Differentiation between diffusion-limited and cerebral blood flow-limited permeability (LogPS).
* Bilinear permeability - LogP dependence: rise of permeability with LogP up to a certain optimum point followed by subsequent decrease due to hydrophobic retention in the membrane (LogPS).
* Ionization-specific partitioning of electrolytes between phospolipid bilayer and plasma (LogPS) or brain tissue lipids and intesrtitial fluid (LogBB).

In both cases fitting was performed in a multi-step approach: the first stage involved determination of parameters describing membrane/plasma partitioning of neutral molecules while in the second stage stage these values wre fixed and eletrolyte-specific passive transport parameters were obtained.

Descriptors used for modeling included key physicochemical properties - octanol/water LogP of neutral species as a determinant of lipophilicity, ion form fractions at pH 7.4 calculated from the respective pKa values, number of hydrogen bond donors and acceptors in the molecule, and McGowan characetristic volume reflecting molecular size. All physicochemical property values were calculated with Algorithm Builder 1.8.

===Prediction accuracy===

Prior to development of both log ''PS'' and log ''BB'' predictive models a part of each data set was reserved for validation purposes and not used in modeling (internal validation set). Additionally, two independent data sets representing another type of experimental data (directly measured ''fu, brain'' values) were extracted from recent publications (Kalvass J. C. et al. ''Drug Metab Dispos.'' '''2007''';35(4):660-6 [http://dmd.aspetjournals.org/cgi/content/full/35/4/660], and Summerfield S. G. et al. ''Xenobiotica.'' '''2008''';38(12):1518-35. [http://www.informaworld.com/smpp/content~db=all?content=10.1080/00498250802499459]) These were used as external validation sets to confirm intrinsic correctness of the obtained model.

Performance of the models on various validation sets is presented in the table below:

{| class="wikitable"
|-
! style="border-top:2px; border-bottom:2px; background:silver;" width="400" | Data set
! style="border-top:2px; border-bottom:2px; background:silver;" width="100" | N
! style="border-top:2px; border-bottom:2px; background:silver;" width="100" | R2
! style="border-top:2px; border-bottom:2px; background:silver;" width="100" | RMSE
|-
| log ''PS'' internal validation set || style="text-align:right;" | 53 || style="text-align:right;" | 0.82 || style="text-align:right;" | 0.49
|-
| log ''fu, brain'' internal validation set || style="text-align:right;" | 137 || style="text-align:right;" | 0.74 || style="text-align:right;" | 0.41
|-
| log ''fu, brain'' external validation set (Kalvass et al., 2007) || style="text-align:right;" | 31 || style="text-align:right;" | 0.73 || style="text-align:right;" | 0.42
|-
| log ''fu, brain'' external validation set (Summerfield et al., 2008) || style="text-align:right;" | 20 || style="text-align:right;" | 0.70 || style="text-align:right;" | 0.36
|}

Statistical parameters obtained for internal and external test sets demonstrate good predictive power of the models with RMSE being close to error of experimental determination in both cases.

The proposed classification scheme was validated using experimentally assigned CNS activity categories for more than 1500 compounds presented in the study by Adenot M. & Lahana R. ''J Chem Inf Comput Sci.'' '''2004''';44(1):239-48. [http://pubs.acs.org/doi/abs/10.1021/ci034205d] After removing compounds, disposition of which is affected by P-gp efflux 92% of the remaining molecules were correctly classified by our model as shown in the figure below:
[[Image:CNS_activity.gif|frame|none|Classification of drugs by presence or absence of CNS activity based on predicted values of log ''BB'' and brain/plasma equilibration rate.]]

===Transport mechanisms===
The predictive models comprising the BBB module only account for '''passive''' transport of analyzed compounds across blood-brain barrier. In order to propose a clear physicochemical explanation of passive diffusion process, the data used for development of both LogPS and LogBB models were thoroughly evaluated to exclude values affected by enzymatic efflux or influx. For such compounds special alerts are displayed in all submodules related to the prediction of BBB transport parameters indicating that observed parameters for these molecules may be higher or lower than predicted values due to presence of carrier-mediated processes, such as facilitated diffusion or P-gp efflux. Considered influx transporters include:
* Amino-acid transport systems (System A, L, y+, x-)
* Glucose carrier GLUT1
* Organic cation/carnitine transporters (OCTN)
* Organic anion transporting polypeptide (OATP)
* Various other carriers specific for nucleotides and other endogenous substances.
</div>
</div>

LogBB - Revision history

Kirilas: Fixed broken links

Kirilas at 09:58, 15 June 2017

Kristina: /* Overview */

Kristina at 13:12, 29 May 2012

Kirilas: /* Features */

Kristina: /* Interface */

Kristina: /* Interface */

Kristina: Created page with "==Overview== This module provides mechanistic predictions of blood brain distribution of drugs and drug-like compounds in rodents. The predictive model is based on a d..."

Kristina: Created page with "==Overview==
This module provides mechanistic predictions of blood brain distribution of drugs and drug-like compounds in rodents. The predictive model is based on a d..."